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Since plasma lipoproteins contain both protein and phospholipid components, either may be involved in
processes such as atherosclerosis. In this study the identification of plasma lipoprotein-associated
phospholipids, which is essential for understanding these processes at the molecular level, are performed.
LC-ESI/MS,LC-ESI-MS/MSandHighPerformanceThinLayerChromatography(HPTLC)analysisofdifferent
lipoprotein fractions collected from pooled plasma revealed the presence of phosphatidylethanolamine (PE),
phosphatidylinositol (PI), and sphingomyeline (SM) only on lipoproteins and phosphatidylcholine (PC),
Lyso-PC on both lipoproteins and plasma lipoprotein free fraction (PLFF). Cardiolipin, phosphatidylglycerol
(PG) and Phosphatidylserine (PS) were observed neither in the lipoprotein fractions nor in PLFF. All three
approachesledtothesameresultsregardingphospholipidsoccurrenceinplasmalipoproteinsandPLFF.Ahigh
abundancyofPEandSMwasobservedinVLDLandLDLfractionsrespectively.Thisstudyprovidesforthefirst
time the knowledge about the phospholipid composition of all defined plasma lipoproteins.
D
espite major advances in the aetiology, prevention and treatment of cardiovascular disease, and in par-
ticular atherosclerosis, it remains the leading cause of mortality and morbidity in Western countries.
Atherosclerosis results from the interaction between genetic and environmental factors modulating the
functions of various cell types and inflammatory molecules within the arterial wall
1,2. Extensive epidemiological
studies have shown that lipoproteins play a major role in atherosclerosis of which LDL cholesterol levels are
directly related to the risk of coronary artery disease and HDL cholesterol levels are inversely related to this risk
3.
Despite lipid cholesterol modification therapies such as LDL-lowering treatments, cardiovascular events still
occur. In addition, compared to plasma cholesterol measurements, much less attention has been given to the
relationship between phospholipids and atherosclerosis.
Lipoproteins are different in phospholipid composition and (apolipo) protein contents
4-6. Moreover, the
apolipoproteins play an important role in lipoprotein stability, binding, and catabolism
7. In addition, plasma
phospholipids transfer protein (PLTP) mediates the transfer of phospholipids from VLDL and LDL to HDL and
is able to modulate HDL size and composition and may also be involved in HDL cellular-mediated efflux of
phospholipids and cholesterol
8-11. The presence of abnormal phospholipids was also shown in patients with
essential hypertension
12. In addition, it was recently shown that the phospholipid composition of HDL plays an
important role in SR-BI- and ABCA1-mediated cholesterol efflux
13,14. Yancey et al.
14 also demonstrated that
Phosphatidylcholine (PC) enrichment of HDL increase the efflux, whereas sphingomyelin decrease the influx of
HDLcholesterol.OtherstudiessuggestthatthephospholipidcompositionofHDLcouldbeakeydeterminantin
a variety of other processes, including the inhibition of adhesion molecules,
15-18 the efflux of cholesterol from
Fu5AH cells to human serum
19 and in its anti-inflammatory and anti-oxidant properties
20,21.
It is also recently suggested that hemodialysis therapy in patients with chronic renal failure play an important
role in dyslipidemic profile of these patients by modification of lipid and phospholipids composition concentra-
tions
22. Furthermore, it has been recently reported that the concentrations of phospholipid composition are
clearly different in acute phase HDL compared to normal HDL
23.
The phospholipid content is one of the factors, which have been suggested to contribute to the closer lateral
molecular packing in LDL
24. The phospholipid composition in surface of lipoprotein particles influences the
binding of apo A–I and thatis the reason why apo A–I is absentin LDLparticles in vivo
24.The impairment of PC
biosynthesis led to the inhibition of VLDL secretion,
25 resulting in the changing of nascent VLDL phospholipids
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26. In addition, VLDL stimulates the contact pathway of
blood coagulation via the exposure of phosphatidylethanolamine
27.
Navabetal.
28haverecentlyshownthatoralphospholipid 1,2-dimyr-
istoyl-sn-glycero-3-phosphocholine (DMPC) in the drinking water
of apoE-deficient mice results in an increase of plasma HDL choles-
terol levels, an improvement in HDL function, and a marked reduc-
tioninatherosclerosis.Moreover,numerousstudieshaveshownthat
phospholipidadministrationleadstothereductionofatherosclerotic
development in vivo
29-31.
Based on above-mentioned evidence, plasma lipoproteins contain
both protein and phospholipid components, either of which may be
involved in the atherosclerosis, inflammation, lipid metabolism, and
haemostaticprocesses.Thus,theplasmalipoproteinfunctionscanbe
manipulated by protein or phospholipids compositions.
After genomics and proteomics, many analytical techniques have
been developed and used to elucidate the human lipidome. A lipi-
domicsapproach may beareliable way to analyze the lipidcomposi-
tion in biological fluids, such as human plasma lipoproteins. A
reliableanalysisofphospholipidmolecules,‘‘lipidomics’’, inthecon-
textofgenomicsandproteomicsisanessentialsteptounderstanding
cellular physiology and pathology and consequently, lipid biology
has become a major research target of the post-genomic revolution
and systems biology.
In our previous study, we have characterized proteins associated
with HDL
32. In this study, liquid chromatography-electrospray ion-
ization/mass spectrometry (LC-ESI-MS) and tandem MS were per-
formed to identify the phospholipids composition of the major
lipoprotein classes. ESI allows for large, non-volatile molecules to
be analyzed directly from the liquid phase. The analysis of main
phospholipids composition of lipoproteins is needed to gain addi-
tional insight into in vivo functions of lipoprotein-phospholipids
content both in normal and pathological states.
Results
Characterization of lipoproteins. High performance gel-permeation
chromatography (HPGC). To investigate whether one-step ultracen-
trifugation provided lipoprotein fractions of acceptable purity, the
collected lipoprotein fractions were subjected to HPGC (figure 1).
TheHDLfractionobtainedbyultracentrifugationresultedinasingle
peak with a retention time of approximately 51 min (figure 1D).
Figure 1 | Panel A shows the major human plasma lipoprotein fractions after one-step salt gradient ultracentrifugation. Panel B shows Cholesterol
profilesofmajorplasmalipoproteinfractionsseparatedbyHighPerformanceGel-PermeationChromatography(HPGC).Lipoproteinfractionsobtainedby
one-stepultracentrifugationweresubjectedtosize-exclusionchromatographyasdescribedinMaterialandMethods.Panel(A)CMfraction,Panel(B)VLDL
fraction, panel (C) LDL fraction, panel (D) HDL fraction, panel E: Plasma lipoproteins free fraction and panel F: standard cholesterol.
www.nature.com/scientificreports
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identical elution patterns, which confirmed that the fraction con-
tained only HDL (figure 1F). VLDL and LDL fractions isolated by
the same method yielded peaks eluting at approximately 28 min and
40 min, respectively (figure 1B and C). Same retention times were
found when commercial LDL and VLDL lipoprotein standards were
analyzed by HPGC, confirming the identity of the peaks (figure 1F).
However, the intermediate-density lipoprotein (IDL) peak was also
detectedinthe VLDLfraction. Nopeaks weredetected intheplasma
lipoprotein free fraction (figure 1E). The IDL fraction obtained by a
combination of ultracentrifugation and HPGS yielded apeak eluting
at approximately 35 min (figure 2). Although the IDL fraction con-
tains LDL, the fraction was very highly enriched in IDL. The subjec-
tion of CM fraction to HPGC resulted in a single peak with a
retention time of 28 min which is similar to elution peak of VLDL
(figure 1A). Although both CM and VLDL fractions yielded a peak
eluting at 28 min, the IDL peak was not observed in CM fraction.
Nephlometry and Western blot analysis of apolipoproteins. Nephelo-
metry was performed to further investigate the results obtained by
HPGC concerning the purity of the isolated lipoprotein fractions
collected by ultracentrifugation. Nephelometric analysis revealed the
presence of apo A–I in the HDL fraction (approximately 1.1 g/l), but
notintheVLDL,IDLandLDLorplasmalipoproteinfreefractions.In
addition,nocross-contaminationofapoBwasobservedintheHDLor
PLFFfractionswhileitwasfoundtobeabundantintheCM(0.52g/l),
VLDL (approximately 0.7 g/l), IDL (0.7 g/l) and LDL (1.2 g/l) frac-
tions. Western blotting with anti-apo B antibodies confirmed the
results obtained by HPGC and nephlometry (figure 3). As depicted
in figure 3, anti-apo B antibodies showed the presence of an intense
band of about 550 kDa corresponding to full length apo B100 in
VLDL, IDL and LDL fractions, but not in HDL and PLFF fractions.
This indicated that the one-step ultracentrifugation protocol resulted
inapurificationofthemajorlipoproteinfractions(andacombination
of ultra and HPGC for IDL purification) without contamination with
other lipoproteins.
Identification of plasma lipoprotein phospholipids composition.
Liquid Chromatography-ElectroSpray Ionization-Mass Spectrometry
(LC-ESI-MS).LC-ESI-MSanalysis inthenegative andpositivemode
led to the identification of different phospholipids associated with
lipoproteins. All samples were run twice in positive ion and negative
mode, allowing the detection of the predominant positive and/or
negative ions of each class of phospholipids. Although we did not
observe CL, PG and PS in all lipoprotein fractions as well as PLFF
(table 1, supplement) the PI (figure 1 A–D, supplement) and SM
were only detected in the plasma lipoprotein fractions (figure 2 A–
Figure 2 | ProteinprofileofIDLfraction. TheultracollectedIDLfraction
were several times exposed to HPGC to purify the IDL, therefore we used
protein profile (to re-use elution for HPGC exposure) instead of
cholesterol profile as described in Material and Methods. However, the
cholesterol profile of ultra collected IDL fraction (before purification with
HPGC) revealed approximately the same elution peak.
Figure 3 | Western blot analysis of purified plasma lipoproteins. Plasma
lipoprotein- associated proteins (20–100 mg) were separated by 6 % (w/v)
SDS-PAGE under denatured conditions, blotted for 20 h and probed with
monoclonal anti-apo B antibodies as described in Materials and Methods.
TheplasmalipoproteinsusedwereCM(lane2,80ug),VLDL(lane3,80ug),
IDL (lane 4, 80 ug), LDL (lane 5, 80 ug), Apo B protein (lane 6, 20 ug), and
HDL (lane 7, 100 ug). The lane 1 is protein marker and lane 8 is plasma
lipoprotein free fraction (PLFF, 100 ug). The molecular weight standards
(Mw) are in kilo Daltons (kDa) and indicated on the left of the figure.
The approximately 500 kDa band is indicated by arrow on the left of the
figure.
Table 1 | Relative quantitative analysis of major phospholipids in 8 plasma lipoprotein fractions as well as in novel plasma lipoprotein free
fraction as plasma control based on the concentration of phospholipids used in standard mixture and expressed in nmol/ml. Plasma
lipoprotein phospholipids composition and PLFF fraction were extracted and applied to one-dimensional, horizontal HPTLC as described
underMaterials andMethodsandlegend offigure9. Sampleswere numberedfrom1to9.Samples were: (1-Chylomicrons, 2-VLDL,3-IDL,
4-LDL, 5-HDL2, 6-PLFF (Control), 7-Lp(a), 8-HDL3 and 9-VHDL. The concentration was expressed as nmol/ml. Molecular weight is abbre-
viated as MW and expressed as kilodalton (kDa).
PL 1 2 3 4 5 6 7 8 9 MW (Da)
L-PC 116 17 5 53 110 63 0 20 51 525
SM 719 173 72 1258 891 5 71 247 65 747
PC 3803 1080 180 6022 230772 61 236 3144 561 791
PI 68 22 6 97 298 0 0 38 14 867
PE 164 64 6 189 633 0 0 96 26 748
Samples (1–9) concentration (nmol/ml).
www.nature.com/scientificreports
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fractions (table 1, supplement,). However, PE was not measured in
PLFF fraction, using LC-ESI-MS approach (see Materials and
Methods; ESI-MS paragraph). Also, CM was not analyzed by LC-
ESI-MS strategy.
LC-ESI-tandemMS(LC-ESI-MS/MS).LC-ESI-MS/MS was applied
to further examine the observed phospholipild profile in the
major lipoprotein fractions and PLFF obtained by LC-ESI-MS
analysis.
LC-ESI-MS/MS strategy revealed the presence of PE (figure 4
A–E), PI (figure 5 A–E) and SM (figure 6 A–E) in all lipoprotein
fractions but not in PLFF. The occurrence of PC and Lyso-PC were
showninalllipoproteinfractionsandPLFF(figure7A–Eandfigure8
A–E respectively), using LC-ESI-MS/MS. Although traces of SM
were found in PLFF fraction, it could have resulted from very small
tracesofVHDLfractionandnotviceversa.Furthermore,theCL,PG,
and PS were also not detected in all fractions, applying this strategy.
Although CL, PG, and PS were not observed in all fractions, lipo-
protein fractions and PLFF obtained by LC-ESI-MS/MS strategy
corresponded with the LC-ESI-MS profiles of the same fractions.
The global intensity of each analyzed phospholipid in the different
fractions was shown in table 1.
High Performance Thin Layer Chromatography (HPTLC). HPTLC
was performed to further confirm the results obtained by MS and
tandem MS. The relative abundance of plasma lipoprotein-associated
phospholipidsasdeterminedbyLC-ESI-MSandLC-ESI-tandemMS
method agrees very well with those results obtained by HPTLC
approach (figure 9). HPTLC method also confirmed the presence of
PE, PI and SM only in lipoprotein fractions and not in PLFF fraction
(figure 9). Moreover, as depicted in figure 9 CL, PG, and PS were not
detected in all fractions applying HPTLC and corresponded to the
results obtained either by LC-ESI-MS or LC- ESI-MS/MS (tandem
MS). Similar results were also obtained by HPTLC as compared to
the other two above-mentioned strategies regarding PC and Lyso-PC
(MS data of HDL-2 and VHDL not shown). Although HPTLC con-
firmed the results obtained by two other strategies, the relative quan-
tityofthemajorphospholipidswascalculatedandshownintable2.As
displayed in table 2, the relative concentration of PC in HDL2 was
tremendously higher than the rest of plasma lipoproteins.
Discussion
To shed light in the role of lipoproteins in patho-physiologic pro-
cesses it is essential to elucidate the make-up of the lipoprotein
particles, i.e. its phospholipid and protein composition. Since recent
Figure 4 | High-performance liquid chromatography electrospray ionization tandem mass spectrometry analysis of plasma lipoproteins and plasma
lipoprotein free fraction. We did not observe any adducts ions like Na or K. positive scan [M 1 H]1. Characteristic part of the parent-scan for
phosphatidylethanolamine (PE) in the corresponding retention time window. ‘3652’ specifies the composition of the protonated molecular ion as a
species with 36 C-atoms in total in the acyl-chains with 2 unsaturated bonds in total; other assignments are analogous. (A) CM fraction, (B) VLDL
fraction, (C) IDL fraction, (D) LDL fraction, (E) HDL fraction and (F) PLFF fraction.
www.nature.com/scientificreports
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genic role of HDL and LDL respectively,
37,38 further studies of these
particles have become even more crucial. In this study, as first step,
we applied a LC-ESI/MS and LC-ESI-MS/MS strategy to lipoprotein
fractions to identify lipoprotein-associated phospholipids. Due to its
highsensitivity,selectivityandspecificity,LC-ESI-MS/MSiswithout
parallelthemostsophisticatedtechniqueforassessing thelipidcom-
position of biological samples such as the phospholipid content of
plasma lipoproteins. Lipoproteins were isolated from human pooled
plasmas and the quality of purity of collected lipoproteins (VLDL,
IDL,LDLand HDLs)was determined using three independent tech-
niques: HPGC, nephelometry and Western blotting
32. Furthermore,
it is basically impossible to separate chylomicrones from VLDL to
collectthepureVLDLorCMduetothecontinuumofVLDLandCM
sizes by ultracentrifugation and HPGC. Although CM and VLDL
fraction could be contaminated with each other, the first fraction
was rich in CM and the second one rich in VLDL. However, we
did not observe any specific differences between the fraction rich
inCMandVLDLfractionwithrespecttophospholipidcomposition.
Nephelometric analysis exhibited that apo A–I (the major con-
stituent of HDL) was only observed in the HDL fractions, whereas
apo B (the major constituent of CM, VLDL, IDL and LDL) was not.
Furthermore, cholesterol analysis, protein analysis and elution
behaviour of ultracentrifugation isolated VLDL, IDL (extra purified
steps by HPGC), LDL, HDL and PLFF confirmed the purity of the
fractions.Finally,WesternblotanalysisrevealedtheabsenceofapoB
intheisolatedHDLfractionsandthepresenceofapoBintheisolated
CM, VLDL, IDL and LDL fractions. These results confirm the utility
of our strategy to collect lipoprotein fractions from plasma that was
not contaminated with other lipoproteins, although CM and VLDL
fractions could be contaminated with each other.
LC-ESI/MS analysis resulted in the identification of sphingomye-
lin,PE, PI, PC and Lyso-PC in all lipoprotein fractions. However, we
didnotobservePG,PSandCLinplasmalipoproteinandlipoprotein
free fractions. This could be due to the presence of only very low
amountsofthesephospholipids(belowthedetectionlimitoftheLC-
ESI-MS technique) in plasma lipoproteins and lipoprotein free frac-
tions under normal conditions in plasma. The very low abundances
ofthesephospholipidswerealsomentionedbyDeguchieta.l.
39.Also,
PG constitutes 2% of the total plasma phospholipids as shown by
Schwars et al.
40 and was confirmed by Uran et al.
41. Since plasma
dividedin9fractionsinthisstudy, theconcentrationofPG(2%)will
bealso divided in these 9 fractions. That could be the reason why PG
was not detected in our samples.
LC-ESI-MS/MS was used as a complementary technique to
improve selectivity and consequently the signal/noise ratio of the
Figure 5 | High-performance liquid chromatography electrospray ionization tandem mass spectrometry analysis of plasma lipoproteins and plasma
lipoprotein free fraction. We did not observe any adducts ions like Na or K. positive scan [M 1 H]1. Characteristic part of the parent-scan for
phosphatidylinositol(PI)inthecorrespondingretentiontimewindow.‘3652’specifiesthecompositionoftheprotonatedmolecularionasaspecieswith
36 C-atoms in total in the acyl-chains with 2 unsaturated bonds in total; other assignments are analogous. (A) CM fraction, (B) VLDL fraction, (C) IDL
fraction, (D) LDL fraction, (E) HDL fraction and (F) PLFF fraction.
www.nature.com/scientificreports
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(LOD).ByusingtheMS/MSmode(classesof)compoundscaneasily
be identified, filtering out the interference of all those compounds
that do not meet the MS/MS conditions. LC-ESI-MS/MS approach
ledtotheidentificationofthesamephospholipidsasweidentifiedin
thedifferentfractionswhenweusedLC-ESI-MS,IndicatingthatLC-
ESI-MS/MS confirms the results obtained by LC-ESI-MS.
It is intriguing to note that PE, PI and SM were only observed in
plasma lipoproteins and not in PLFF. This finding confirmed the
specificity of our utility to identify lipoprotein-associated phospho-
lipids. Furthermore, on searching the literature, we were unable to
find any study in which the plasma lipoprotein free fractions were
used as control for plasma lipoproteins. In addition, HPTLC was
used as an alternative method to support and confirm the results
obtained by MS and tandem MS approach regarding phospholipids
composition of the major plasma lipoproteins. Three independent
strategies led to the identification of a similar lipoprotein-associated
phospholipids pattern, indicating a high confidence in the obtained
results. Interestingly, the molecular profile appeared to be conserved
betweenthedifferentlipoproteinseventhoughtheconcentrations of
the lipid classes show slight differences except for PC species 3852,
3854 and 4056 in CM fraction. These three PC species were only
detectedinCMfractionandwerecompleteabsentinotherfractions.
Although LC-ESI-MS and LC-ESI-MS/MS were applied as quali-
tative approach, HPTLC was used as semi-quantitative in this study.
MS and tandem MS were used as qualitative approach, because of
threepoints: 1-the useof different internalstandard foreach plasma
lipoprotein fraction, 2; the use of different internal standard for each
main phopholipid and lipid species and 3; the combination of step 1
and2increasethecomplexityofsamplesandinturntheuseofmany
different internal standards hampered to obtain correct quantifica-
tion. This complexity was also described by Uran et al.
41. However,
Uran et al.
41 have shown a limit detection of 0.1–5 ng for blood-
associated phospholipids. For this reason, HPTLC was used as
semi-quantitative approach in this study and not MS approach.
Numerous studies show that low HDL-C can be considered as an
independent riskfactorof atherosclerosis even whenLDL-C islow
42.
In addition, it is also well studied that increased HDL-C reduces the
riskforcardiovasculardisease
42,43.Althoughtherearemanyavailable
strategiestoincreasetheHDL-C,thepresentavailabletherapieswith
the current drugs have a limited effect because of low efficacy and
severe side effects of these drugs
29. An alternative therapy for the
increase of the HDL-C levels is PI therapy via diet as shown recently
by Burgess et al. and the others
29-31. Burgess et al. have shown that PI
stimulates cholesterol reverse transport via an increased efflux from
peripheral tissues to HDL and in turn the transport of cholesterol
Figure 6 | High-performance liquid chromatography electrospray ionization tandem mass spectrometry analysis of plasma lipoproteins and plasma
lipoprotein free fraction. We did not observe any adducts ions like Na or K. positive scan [M 1 H]1. Characteristic part of the parent-scan for
sphingomyeline (SM)inthecorrespondingretentiontimewindow.‘3451’specifiesthecompositionoftheprotonatedmolecular ionasaspecieswith34
C-atoms in total in the acylchain and alkyl chain of the sphingosine moiety with 1 unsaturated bond in total; other assignments are analogous. (A) CM
fraction, (B) VLDL fraction, (C) IDL fraction, (D) LDL fraction, (E) HDL fraction and (F) PLFF fraction.
www.nature.com/scientificreports
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29-31.
TheyhavealsodemonstratedthatwhenPIistakenorallyduringtwo
weeks therapy leads on the one side the increase of apo-AI concen-
trations and on the other side the decrease of plasma triglyceride
levels
29-31. Our results revealed that PI is only present on plasma
lipoproteins, and this may increases the specificity of therapy with
PI via diet to affect the lipoprotein composition levels. Although the
mechanism study of PI effect on lipoprotein is beyond our study, the
PItherapyviadietisverysimpleandperformablewithoutmajorand
severe side effects.
AnothernovelfindinginthisstudyisalsothepresenceofSMonly
on lipoproteins. Although SM plays a major role in the constitution
of all lipoproteins, the physiological function of SM in plasma is not
until recently clear. Papasani et al.
44 have shown that SM inhibits the
oxidation of lipoproteins. Furthermore, Rey et al.
45 have shown in
reconstituted high density lipoproteins studies that SM influences
thestructureofdiscoidalandsphericalrHDLaswellasitinhibitsthe
LCATreactionindiscoidalrHDL.Ithasbeenrecentlysuggestedthat
presence of SM in the lipoprotein surface involved in lipoprotein
lipase-mediated lipolysis, and that cholesterol enrichment in the
lipoprotein surface does not affect lipolysis
46,47. Moreover, it has
been reported that SM can be used as marker for the clearance of
remnant-like particles
48.Also, Jiang etal.have suggested that plasma
SM concentration is a risk factor for atherosclerotic process
49.
Although the function of SM in lipoproteins remains to be fully
clarified, the SM could be also considered as an alternative therapy
and pharmacological intervention to affect lipoprotein levels. To our
knowledge, the observed effects of PI
29-31andSM
43-48in plasma could
be only possible via lipoproteins, since PI and SM were only present
on lipoproteins (with high intensity of SM in LDL fraction) and not
detected in plasma lipoprotein free fractions.
Next to other studies,
19,27,50 our approach also revealed the pres-
enceofPEonlipoproteins.Recently,Agrenetal.
51demonstratedthat
there is a selective secretion of PE and sphingomyelin molecular
species during VLDL secretion when they compare the molecular
species phospholipids content of VLDL with liver phospholipids
composition. Furthermore, it has been recently shown that
Prothrombinase enhancement through quantitative and qualitative
changesappeartoaffectverylowdensitylipoproteinincomplexwith
C-reactive protein, and the qualitative changes appeared to be
resulted from a deficiency of PE in VLDL from disseminated intra-
vascular coagulation patients with the biphasic waveform
52. In addi-
tion, Phosphatidylethanolamine N-methyltransferase appears to be
an essential component in the secretion of apoB100-containing
Figure 7 | High-performance liquid chromatography electrospray ionization tandem mass spectrometry analysis of plasma lipoproteins and plasma
lipoprotein free fraction. We did not observe any adducts ions like Na or K. positive scan [M 1 H]1. Characteristic part of the parent-scan for
phosphatidylcholine(PC)inthecorrespondingretentiontimewindow.‘3452’specifiesthecompositionoftheprotonatedmolecularionasaspecieswith
34 C-atoms in total in the acyl-chains with 2 unsaturated bonds in total; other assignments are analogous. (A) CM fraction, (B) VLDL fraction, (C) IDL
fraction, (D) LDL fraction, (E) HDL fraction and (F) PLFF fraction.
www.nature.com/scientificreports
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53. Since PE is only present in lipoproteins, (with highest
abundancy in VLDL fraction) its physiological role could be only
possible via lipoproteins.
LC-ESI/MSanalysisfurtherrevealedthepresenceofPCandLyso-
PConlipoproteins.Parthasarathyetal.havereportedthat40%ofthe
PC in LDL is converted to lyso-PC during oxidized modification.
Also, the lyso-PC concentration is shown to be increased in athero-
sclerotic plaques in mice fed an atherogenic diet
54,55. Furthermore,
Lyso-PCinduceshumancoronaryarterySmoothmusclecellsmigra-
tion
56. In addition, Lyso-PC increased in atherogenic lipoproteins
and atherosclerotic lesions, and has been shown to stimulate tran-
scription of avariety of endothelial genes relevant to atherogenesis
57.
In summary, this study resulted in the identification of 5 phospho-
lipids associated with lipoproteins of which PE, PI and SM were only
present in lipoproteins. The role of these identified lipoprotein-assoc-
iated phospholipids in atherothrombosis awaits further investigation
andmayprovidenewinsightsintothemechanism(s)ofatherothrom-
botic diseases and the future pharmacological intervention.
Methods
Materials. Human blood was drawn from overnight-fasted normal healthy volun-
teersafterinformedconsent,byvenipunctureintotubescontainingsodium-citrateas
anticoagulant. Subsequently, plasma was obtained by centrifugation at 1,000 x g for
15 minutes at 4 uC and used freshly or stored at 280uC for further analysis. All
experiments were performed in accordance with relevant guidelines and regulations
and had the approval of the local Medical ethical committee (Academic Medical
Center Amsterdam/ Univerisity Medical Center Groningen).
Lipoprotein isolation by salt-gradient ultracentrifugation. One-step ultracentri-
fugation was used according to Kleinfeld et al.
33 with some modifications
(omission of sucrose in the salt gradient, and use of a 103,000 x g instead of a
200,000 x g centrifugation step) to obtain the major lipoprotein fractions (VLDL,
IDL, LDL, and HDL) and HDL-2 and VHDL as well as Plasma Lipoprotein Free
Fraction (PLFF). In this study, all plasma lipoprotein fractions were analyzed
except Lipoprotein small a (LPa) and that was due to very small amount of
extracted lipid fraction. The collected lipoprotein fractions were concentrated by
concentrator (Eppendorf) and were freshly used in the experiments and the rest
stored for 10 days at 4uC. Only for the isolation of chylomicrons (CM) we
applied other approach.
CM isolation. 12 ml non-fasted plasma was spun in a SW41.14 rotor for 1 hour at
29000 rpm in a Beckman ultracentrifuge. The top 3 ml was collected and spun under
the same conditions. The top approximately 2.5 ml was again eluted and spun under
the same circumstances. Finally, the top 2 ml collected fraction (rich in CM) was
subjected to one-step ultracentrifugation according to Kleinfeld et al.
33 with some
modifications. This strategy was taken to remove as much VLDL possible from the
chylomicronsfraction.Allultra,HPGCandmassspectrometryexperimentsinvolved
CM fraction were separately performed en analyzed.
Figure 8 | High-performance liquid chromatography electrospray ionization tandem mass spectrometry analysis of plasma lipoproteins and plasma
lipoprotein free fraction. We did not observe any adducts ions like Na or K. positive scan [M 1 H]1. Characteristic part of the parent-scan for lyso-
phosphatidylcholine (LPC) in the corresponding retention time window. ‘1850’ specifies the composition of the protonated molecular ion as a species
with 18 C-atoms in the acyl-chain with 0 unsaturated bonds in total; other assignments are analogous. (A) CM fraction, (B) VLDL fraction, (C) IDL
fraction, (D) LDL fraction, (E) HDL fraction and (F) PLFF fraction.
www.nature.com/scientificreports
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and protein analysis. The cholesterol profiles of the major lipoprotein types were
determined applying HPGC
32-36.6 0ml of lipoprotein fractions collected by ultra-
centrifugation wasintroduced togel-permeationchromatographyusingaSuperose6
HR 10/30 column (Pharmacia Biotech, Uppsala, Sweden)
32-35. Chromatographic
profiles of commercially available plasma lipid standards (SKZL, Nijmegen, The
Netherlands) served as a reference. To obtain a purified ultra IDL fraction, Ultra IDL
fractionwasrepeatedly exposed toHPGC.Theprotein analysiswasusedforthe ultra
collected IDL fraction. All conditions for the protein analysis of the ultra collected
IDL fraction are the same as above-mentioned procedure meant for the cholesterol
analysis.
Nephelometry. Apo A–I and apo B content in the lipoprotein fractions were mea-
sured by immunoprecipitation using nephelometry in a BN ProSpec nephelometer
proteinanalyser(DadeBehring,Marburg,Germany)accordingtothemanufacturer’s
instruction. The reagents for the quantitative determination of apo A–I and apo B
were purchased by Dade Behring (Dade Behring, Marburg, Germany).
Western blot analysis. 50-100 mg of protein present in the lipoprotein and plasma
lipoprotein free fractions were denatured and separated by 7.5 % (w/v) SDS-PAGE
and transferred from the gel to low fluorescent polyvinylidene difluoride (LPF-
PVDF)membranes(GEHealthcare Biosciences).Theblotswerethenblockedat4uC
for overnight. After blocking, blots were incubated with a monoclonal antibody
againstapoB(178444,Calbiochem,Darmstadt,Germany).ApolipoproteinBprotein
was purchased by sigma (Gmbh, Germany). Bound antibodies were detected
with a CyDye-coupled goat anti-mouse antibody according to the manufacturer’s
instructions for ECL Plex Western Blotting System (GE Healthcare Biosciences).
PageRuler prestained protein ladder (Fermentas, Germany) were run in parallel. The
protein concentration of the lipoprotein fractions was determined by absorbance at
280 nm (an OD of 1 equals 1 mg/mL).
Lipoprotein and plasma lipoprotein free fraction associated Phospholipid
extraction. The phospholipids from 200 ml of each plasma lipoprotein and lipo-
protein free fractions (three independent Lipoprotein isolation by salt-gradient
ultracentrifugation) were extracted with 4 ml of ice-cold solution of chloroform:
methanol (151 v/v). The suspension was incubated for 30 min at 4 uC. Subsequently,
the mixture was centrifuged at 4,000 rpm for 15 min at 4 uC. The supernatant was
collected and the pellets were treated with 3 ml chloroform: methanol (251 v/v)
followed by incubation and centrifugation. The collected supernatants were
pooled, pelletted under nitrogen gas, solubilized in chloroform: methanol: water
(5054555v/v)andstoredat-80uC.Thisphospholipidextractionapproachisasingle-
phase extraction (monophasic)
58. Based on this monophasic approach, we assume
that we did not loose any phospholipids in our plasma lipoprotein fractions.
Liquid Chromatography- ElectroSpray Ionization-MS (LC-ESI-MS). LC. The LC
system consisted of an HP1100 series binary gradient pump, a vacuum degasser, a
column temperature controller (all from Hewlett Packard, Wilmington, DE, USA)
and a Gilson 231 XL autosampler (Gilson, Villiers-le-Bel, France). 20 mL of sample
was loaded onto an analytical LiChrosphere Si 60 column (25032 mm, 5 mm
particle size, Merck, Darmstadt, Germany) and the column temperature was main-
tained at 22 uC. Samples were eluted with a flow rate of 0.3 mL/min and a linear
gradientbetweensolutionA(CH3OH/H2O,90510v/v,0.1%NH4OH)andsolutionB
Figure 9 | Separation of phospholipids from plasma lipoprotein fractions and plasma lipoprotein free fraction by HPTLC. Plasma lipoprotein
phospholipid composition and PLFF fraction were extracted and applied to one-dimensional, horizontal HPTLC as described under Materials and
Methods. Representative separations are shown of a mixture of purified (ST5standard) phospholipids (lane 1 (10 ml), 2 and 12 (20 m)). The following
concentration ofphospholipids (PL)were usedinstandard mixture andexpressed inng/ml(Lyso-PC 51,SM101.8,PC 100,PI50,PE49.7,Lyso-PS 67.2,
Lyso-PE 53 and PS 50.2). The following volumes of lipoprotein phospholipids extracts were utilized in HPTLC (Chylomicrons (lane 3, 3 ml), VLDL
(lane4,4 ml),IDL(lane5,5 ml),LDL(lane6,2 ml),HDL2(lane7,2 ml),PLFF(lane8,5 ml),Lp(a)(lane9,2 ml),HDL3(lane10,4 ml),andVHDL(lane11,
5 ml). The different phospholipids composition of standard mixture is indicated on the left and lane number on the top of figure.
Table 2 | Global relative abundance of each phospholipid based on the intensity of the most intense peak.
PLF
PHOSPHOLIPIDS
PE PG PS PI PC SM LP-C CL
VLDL 11111 nd nd 1111 1111 111 1 nd
IDL 1 nd nd 11 111 11 11111 nd
LDL 1 nd nd 111 1111 11111 11 nd
HDL2 1 nd nd 111 1111 11 1 nd
HDL3 11 nd nd 11111 11111 111 11 nd
VHDL 1 nd nd 1111 111 11 111 nd
PLFF nd nd nd nd 1 1 1111 nd
Relativeabundanceofphospholipidsinthedifferentplasmalipoproteinfractionswereindicatedby1,Verysmalltracesofadetectedphospholipidsareindicatedbysmall1.Theabbreviationsare:Plasma
lipoprotein fraction (PLPF), Plasma lipoprotein free fraction (PLFF) and not detected (nd). The results for CM fraction was obtained in a separate tandem MS run, hence relative intensity of CM were not
included in this table. A similar pattern was observed for the phospholipids composition of CM and other lipoprotein fractions, although CM fraction was separately analyzed. Please see the list of
abbreviation in supplement.
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T50 min, 20% A and 80% B towards t 5 5 min, 100% A; t5528 min 100% A;
t5828.1 minchangeto100%B;t58.1214 min100%B.t514214.1 min:return
back to the starting composition; a flow of 0.5 ml/min was used to equilibrate the
column. All gradient steps were linear, and the total analysis time, including the
equilibration, was 18 min.
A splitter between the LC column and MS allowed introduction of eluant with a
flowof30 ml/min.Anelectricallyoperatedvalveselectedtheintroductionofeluantin
the MS between t 5 3 and 14 min.
ElectroSpray Ionization-Mass Spectrometry (ESI-MS). A Quattro II triple-quad-
rupolemassspectrometer(Micromass,Manchester,UK),wasusedinthepositiveand
negative electrospray ionization (ESI) mode. Nitrogen was used as nebulizing gas
and argon was used as collision gas at a pressure of 2.5310
23 mBar (collision energy
20–40 eV). The capillary voltage used was 3 KV. The source temperature was set at
80uCandoptimalconevoltagewas45V.Fullscanswereacquiredbetween(1/-)m/z
400 and (1/-) m/z 1000 in 3s/scan. Specific phospholipid identities were confirmed
by the characteristic constant neutral loss or parent scans in the corresponding
retention time windows (for PE). All LC-ESI/MS experiments were performed with
two independent lipoprotein isolation by salt-gradient ultracentrifugation.
Liquid Chromatography –ESI-tandem Mass Spectrometry (LC-ESI-MS/ MS). LC.
Chromatographic separation was achieved on a Surveyor modular LC System
(Thermo Finnigan Corporation, San Jose, CA, USA) consisting of a thermostated
autosampler, a low-flow quaternary MS pump and a 2.13250 mm silica column,
5 mm (particle size) (Merck, Darmstadt, Germany).
Samples were eluted with a flow rate of 0.3 ml/min and a linear gradient between
solutionA(CH3OH/H2O,85515v/v,0.1%NH4OH)andsolutionB(CHCl3/CH3OH,
9753v/v,0.01%NH4OH).Thegradientwasprogrammed:fromT50min,20%Aand
80%BtowardsT510min,100%A;T510212min100%A;T512212.1 minchange
to 100% B; T512.1217 min 100% B. T517217.1 min: return back to the starting
composition. A splitter between the LC column and the mass spectrometer was used;
75 ml/min was introduced into the mass spectrometer.
ESI-MS/MS analysis. MS/MS analyses were performed on a TSQ Quantum AM
(Thermo Finnigan Corporation, San Jose, CA, USA) operated alternating in the
negative- and positive ion electrospray ionization (ESI) mode in consecutive runs.
The SID was set at 10 V; spray voltage was 3600 V and the capillary temperature was
300 uC. In the MS/MS experiments Ar was used as collision gas at a pressure of
0.5 mtorr; collision energy ranged between 20–40 eV for the different optimized
transitions.Inthenegativemodemassspectrawereobtainedbycontinuousscanning
between m/z 400 - m/z 1000 (2s/scan). In the positive mode characteristic constant
neutral loss (CNL) or parent (P) scans were used to selectively detect specific
phospholipids in their corresponding retention time windows: CNL (141) for PE,
CNL(172)forPG,(260)forPI,CNL(185)forPS,CNLandP(184)forPC,LPC,SM
59.
CNL (172) for PG and (260) for PI was described previously by Sommer et al.
60,a n d
Cole et al.
61
Cardiolipins are easily identified based upon their retention time and typical
clusters of doubly charged ions as described previously by Houtkooper et al.
58 and
Han et al.
62 and we applied this approach to determine CL in plasma lipoprotein
samples.
HighPerformanceThinLayerChromatography(HPTLC).HPTLCwasperformed
as described previously.
36 Very shortdescription:TLC was applied on HPTLC plates,
which is purchased from Merck (Darmstadt, Germany). The impurities of plates
were removed by methanol: ethyl acetate treatment (654) in a Camag horizontal
developing chamber. Theplateswereactivatedfor 10 min at 130uC. Samples and one
mixtureofphospholipidsstandardswereappliedtooneHPTLC-plate.Subsequently,
the plate was developed in a Camag horizontal developing chamber.
The HPTLC-plate was dried under an air stream (40uC) on a heating plate
(DESAGA, Heidelberg, Germany) for 10 min at 40uC. Finally, phospholipids were
separated as described previously.
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